# Phase I Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of HSK39004 Dry Powder Inhalation

> **NCT06971198** · PHASE1 · COMPLETED · sponsor: **Haisco Pharmaceutical Group Co., Ltd.** · enrollment: 26 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** HSK39004
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06971198
- **Lead sponsor:** Haisco Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-02-10
- **Primary completion:** 2025-03-28
- **Final completion:** 2025-05-06
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2025-05-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06971198

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06971198, "Phase I Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of HSK39004 Dry Powder Inhalation". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06971198. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*